Applications of Botulinum toxin in urogynaecology

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 133, Issue 1, 2007, Pages 4-11

  Sinha, D ^a   Karri, K ^a   Arunkalaivanan, A S ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Botulinum toxin; Botulinum toxin A; Detrusor overactivity; Detrusor sphincter dyssynergia; Interstitial cystitis; Neurogenic bladder; Pelvic pain; Spinal cord injury

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ABSENCE OF SIDE EFFECTS; BLADDER DYSFUNCTION; BLADDER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENDOCYTOSIS; HUMAN; IDIOPATHIC DISEASE; INJECTION; INTERNALIZATION; INTERSTITIAL CYSTITIS; MALAISE; MITOSIS INHIBITION; MUSCLE WEAKNESS; NEUROGENIC BLADDER; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; URINE RETENTION; URODYNAMICS; XEROSTOMIA;

EID: 34250783876     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.12.014     Document Type: Review

References (49)

1. Schiavo G., Santucci A., Dasgupta B.R., et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 335 (1993) 99-103
2. Harper M., Fowler C.J., and Dasgupta P. Botulinum toxin and its applications in the lower urinary tract. BJU Int 93 (2004) 702-706
3. Petit H., Wiart L., Gaujard E., et al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36 (1998) 91-94
4. Dykstra D.D., and Sidi A.A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71 (1990) 24-26
5. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., and Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 (1988) 919-922
6. Yokoyama T., Kumon H., Smith C.P., Somogyi G.T., and Chancellor M.B. Botulinum toxin treatment of urethral and bladder dysfunction. Acta Med Okayama 56 (2002) 271-277
7. Wenzel R.G. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm 61 (2004) S5-S10
8. Leippold T., Reitz A., and Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44 (2003) 165-174
9. Arnon S.S., Schechter R., Inglesby T.V., et al. Botulinum toxin as a biological weapon: medical and public health management. Jama 285 (2001) 1059-1070
10. Bayliss M., Wu C., Newgreen D., Mundy A.R., and Fry C.H. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol 162 (1999) 1833-1839
11. O'Reilly B.A., Kosaka A.H., Knight G.F., et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 167 (2002) 157-164
12. Brady C.M., Apostolidis A.N., Harper M., et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 93 (2004) 770-776
13. Brady C.M., Apostolidis A., Yiangou Y., et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol 46 (2004) 247-253
14. Apostolidis A., Popat R., Yiangou Y., et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174 (2005) 977-982 [discussion 982-3]
15. Sahai A., Khan M., Fowler C.J., and Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 24 (2005) 2-12
16. Harper M., Popat R.B., Dasgupta R., Fowler C.J., and Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92 (2003) 325-326
17. Radziszewski P., and Borkowski A. Botulinum toxin type A intravesical injections for instable bladder overactivity. Eur Urol Suppl 1 1 (2002) 134 [Abstract 526]
18. Dykstra D., Enriquez A., and Valley M. Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14 (2003) 424-426
19. Ghei M., Maraj B.H., Miller R., et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 174 (2005) 1873-1877 [discussion 1877]
20. Popat R., Apostolidis A., Kalsi V., Gonzales G., Fowler C.J., and Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174 (2005) 984-989
21. Schmid D.M., Sauermann P., Werner M., et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176 (2006) 177-185
22. Schurch B., Stohrer M., Kramer G., Schmid D.M., Gaul G., and Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164 (2000) 692-697
23. Reitz A., Stohrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
24. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
25. Jost W.H., and Naumann M. Botulinum toxin in neuro-urological disorders. Mov Disord 19 Suppl. 8 (2004) S142-S145
26. Smith C.P., Nishiguchi J., O'Leary M., Yoshimura N., and Chancellor M.B. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65 (2005) 37-41
27. Phelan M.W., Franks M., Somogyi G.T., et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165 (2001) 1107-1110
28. Kuo H.C. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61 (2003) 550-554
29. Fowler C.J., Betts C.D., Christmas T.J., Swash M., and Fowler C.G. Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 70 (1992) 387-389
30. Smith C.P., Radziszewski P., Borkowski A., Somogyi G.T., Boone T.B., and Chancellor M.B. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 64 (2004) 871-875 [discussion 875]
31. Rackley R., and Abdelmalak J. Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep 5 (2004) 381-388
32. Jarvis S.K., Abbott J.A., Lenart M.B., Steensma A., and Vancaillie T.G. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 44 (2004) 46-50
33. Haferkamp A., Schurch B., Reitz A., et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 46 (2004) 784-791
34. Bakheit A.M., Fedorova N.V., Skoromets A.A., Timerbaeva S.L., Bhakta B.B., and Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 75 (2004) 1558-1561
35. Grosse J., Kramer G., and Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 (2005) 653-659
36. Riccabona M., Koen M., Schindler M., et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171 (2004) 845-848 [discussion 848]
37. Naumann M., and Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20 (2004) 981-990
38. De Laet K., and Wyndaele J.J. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 43 (2005) 397-399
39. Rapp D.E., Lucioni A., Katz E.E., O'Connor R.C., Gerber G.S., and Bales G.T. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63 (2004) 1071-1075
40. Kuo H.C. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63 (2004) 868-872
41. Werner M., Schmid D.M., and Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192 (2005) 1735-1740
42. Rajkumar G.N., Small D.R., Mustafa A.W., and Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96 (2005) 848-852
43. Schulte-Baukloh H., Michael T., Sturzebecher B., and Knispel H.H. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44 (2003) 139-143
44. Giannantoni A., Di Stasi S.M., Stephen R.L., Bini V., Costantini E., and Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172 (2004) 240-243
45. Kessler T.M., Danuser H., Schumacher M., Studer U.E., and Burkhard F.C. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 24 (2005) 231-236
46. Schurch B., Hauri D., Rodic B., Curt A., Meyer M., and Rossier A.B. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155 (1996) 1023-1029
47. Kuo H.C. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 170 (2003) 1908-1912
48. de Seze M., Petit H., Gallien P., et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42 (2002) 56-62
49. Gallien P., Robineau S., Verin M., Le Bot M.P., Nicolas B., and Brissot R. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79 (1998) 715-717